Apellis Pharmaceuticals, Inc. (APLS): Price and Financial Metrics
APLS Price/Volume Stats
| Current price | $49.93 | 52-week high | $94.75 |
| Prev. close | $48.72 | 52-week low | $19.83 |
| Day low | $48.62 | Volume | 1,245,761 |
| Day high | $50.41 | Avg. volume | 1,483,787 |
| 50-day MA | $58.73 | Dividend yield | N/A |
| 200-day MA | $51.82 | Market Cap | 6.02B |
APLS Stock Price Chart Interactive Chart >
Apellis Pharmaceuticals, Inc. (APLS) Company Bio
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company was founded in 2009 and is based in Crestwood, Kentucky.
Latest APLS News From Around the Web
Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted ConferenceWALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the even |
Wall Street Analysts Just Trimmed Price Targets for These 10 StocksIn this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. In the latest market developments on December 18, Asian stocks experienced a notable decline, […] |
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GAThe CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines. |
Apellis Crashes 17% As It Stares Down A Likely European RejectionApellis said Thursday it expects European regulators to reject its eye disease drug, Syfovre. APLS stock tumbled below its 200-day line. |
UPDATE 1-Apellis says EU regulator panel may not back its eye disease drugApellis Pharmaceuticals said on Thursday the European drug regulator's advisory panel may decline to back an authorization for its drug to treat a chronic eye disease, sending its shares down more than 14% in premarket trading. The company said it was informed on Wednesday that the panel may vote against the drug, a form of pegcetacoplan directly injected in the back of the eye, at the next meeting on Jan. 22-25. |
APLS Price Returns
| 1-mo | -10.08% |
| 3-mo | -24.63% |
| 6-mo | 5.03% |
| 1-year | -42.89% |
| 3-year | 12.94% |
| 5-year | 147.30% |
| YTD | -16.59% |
| 2023 | 15.76% |
| 2022 | 9.37% |
| 2021 | -17.34% |
| 2020 | 86.81% |
| 2019 | 132.15% |
Loading social stream, please wait...